By Ian Walker

AstraZeneca PLC (AZN.LN) said Wednesday that a phase 3 "Neptune" trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer didn't meets its primary endpoint.

The pharmaceutical company said the trial aimed to improve overall survival compared with standard of care chemotherapy, in previously-untreated Stage IV (metastatic) non-small-cell lung-cancer patients.

However Astra said the safety and tolerability profile for combination of Imfinzi and tremelimumab was consistent with previous trials.

"We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve Immuno-Oncology approaches for patients with metastatic non-small cell lung cancer," Executive Vice President, Oncology R&D, Jose Baselga said.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

August 21, 2019 02:26 ET (06:26 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca